Tenpoint Therapeutics’ name refers to the time it takes for an image to hit the retina and be processed by the brain. The regenerative medicine startup is developing cell therapies it hopes restore that vision capability for patients with degenerative eye disorders.
By selling U.S. rights to Yutiq, EyePoint Pharmaceuticals gets $75 million cash to support its drug pipeline. The company’s lead product candidate is in mid-stage development for wet age-related macular degeneration and non-proliferative diabetic retinopathy.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Two years after the close of the merger that formed Viatris, the company is acquiring Oyster Point Pharma and Famy Life Sciences to expand its scope in ophthalmology, one of three therapeutic areas it is now focusing on for revenue growth.
Ascidian Therapeutics is developing therapies for inherited disorders that work by editing RNA with an approach that could offer advantages over currently available genetic medicines. The biotech’s lead program is in preclinical development for Stargardt disease, a rare eye disorder caused by multiple genetic mutations.
The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline.
AMD in particular impacts as many as 11 million Americans. About 15% of those affected have neovascular or wet AMD. It’s a devastating disease that can lead to irreversible vision loss.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
MedArrive providers will use Spect’s artificial intelligence-enabled telemedicine platform to screen patients at home for eye diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration.